209 related articles for article (PubMed ID: 37407956)
41. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ
Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374
[TBL] [Abstract][Full Text] [Related]
42. Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo-controlled double-blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi-center placebo-controlled double-blind randomized trial.
Tanaka A; Shimabukuro M; Machii N; Teragawa H; Okada Y; Shima KR; Takamura T; Taguchi I; Hisauchi I; Toyoda S; Matsuzawa Y; Tomiyama H; Yamaoka-Tojo M; Ueda S; Higashi Y; Node K
J Diabetes Investig; 2020 Nov; 11(6):1551-1563. PubMed ID: 32537887
[TBL] [Abstract][Full Text] [Related]
43. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
Santos-Gallego CG; Garcia-Ropero A; Mancini D; Pinney SP; Contreras JP; Fergus I; Abascal V; Moreno P; Atallah-Lajam F; Tamler R; Lala A; Sanz J; Fuster V; Badimon JJ
Cardiovasc Drugs Ther; 2019 Feb; 33(1):87-95. PubMed ID: 30675708
[TBL] [Abstract][Full Text] [Related]
44. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Ferrannini E; Seman L; Seewaldt-Becker E; Hantel S; Pinnetti S; Woerle HJ
Diabetes Obes Metab; 2013 Aug; 15(8):721-8. PubMed ID: 23398530
[TBL] [Abstract][Full Text] [Related]
45. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Packer M; Anker SD; Butler J; Filippatos G; Pocock SJ; Carson P; Januzzi J; Verma S; Tsutsui H; Brueckmann M; Jamal W; Kimura K; Schnee J; Zeller C; Cotton D; Bocchi E; Böhm M; Choi DJ; Chopra V; Chuquiure E; Giannetti N; Janssens S; Zhang J; Gonzalez Juanatey JR; Kaul S; Brunner-La Rocca HP; Merkely B; Nicholls SJ; Perrone S; Pina I; Ponikowski P; Sattar N; Senni M; Seronde MF; Spinar J; Squire I; Taddei S; Wanner C; Zannad F;
N Engl J Med; 2020 Oct; 383(15):1413-1424. PubMed ID: 32865377
[TBL] [Abstract][Full Text] [Related]
46. Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study.
Requena-Ibáñez JA; Santos-Gallego CG; Rodriguez-Cordero A; Vargas-Delgado AP; Mancini D; Sartori S; Atallah-Lajam F; Giannarelli C; Macaluso F; Lala A; Sanz J; Fuster V; Badimon JJ
JACC Heart Fail; 2021 Aug; 9(8):578-589. PubMed ID: 34325888
[TBL] [Abstract][Full Text] [Related]
47. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
Connelly KA; Zhang Y; Desjardins JF; Nghiem L; Visram A; Batchu SN; Yerra VG; Kabir G; Thai K; Advani A; Gilbert RE
Cardiovasc Diabetol; 2020 Feb; 19(1):13. PubMed ID: 32035482
[TBL] [Abstract][Full Text] [Related]
48. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
Omar M; Jensen J; Ali M; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Tuxen CD; Möller S; Gustafsson F; Køber L; Schou M; Møller JE
JAMA Cardiol; 2021 Jul; 6(7):836-840. PubMed ID: 33404637
[TBL] [Abstract][Full Text] [Related]
49. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes.
Yabe D; Shiki K; Suzaki K; Meinicke T; Kotobuki Y; Nishida K; Clark D; Yasui A; Seino Y
BMJ Open; 2021 Apr; 11(4):e045844. PubMed ID: 33827843
[TBL] [Abstract][Full Text] [Related]
50. The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.
Ring A; Brand T; Macha S; Breithaupt-Groegler K; Simons G; Walter B; Woerle HJ; Broedl UC
Cardiovasc Diabetol; 2013 Apr; 12():70. PubMed ID: 23617452
[TBL] [Abstract][Full Text] [Related]
51. Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study.
Thiele K; Rau M; Hartmann NK; Möllmann J; Jankowski J; Böhm M; Keszei AP; Marx N; Lehrke M
Diabetes Obes Metab; 2021 Dec; 23(12):2814-2818. PubMed ID: 34378852
[TBL] [Abstract][Full Text] [Related]
52. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
Cherney DZI; Dekkers CCJ; Barbour SJ; Cattran D; Abdul Gafor AH; Greasley PJ; Laverman GD; Lim SK; Di Tanna GL; Reich HN; Vervloet MG; Wong MG; Gansevoort RT; Heerspink HJL;
Lancet Diabetes Endocrinol; 2020 Jul; 8(7):582-593. PubMed ID: 32559474
[TBL] [Abstract][Full Text] [Related]
53. The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predict left ventricular thrombus resolution in acute myocardial infarction without percutaneous coronary intervention.
Sia CH; Leow AS; Tan BY; Low CJ; Kaur R; Yeo TC; Chan MY; Tay EL; Yeo LL; Yap ES; Loh JP
Thromb Res; 2020 Oct; 194():16-20. PubMed ID: 32559523
[TBL] [Abstract][Full Text] [Related]
54. Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction.
Omar M; Jensen J; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Möller S; Ali M; Gustafsson F; Køber L; Borlaug BA; Schou M; Møller JE
J Am Coll Cardiol; 2020 Dec; 76(23):2740-2751. PubMed ID: 33272368
[TBL] [Abstract][Full Text] [Related]
55. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
Fitchett D; Inzucchi SE; Cannon CP; McGuire DK; Scirica BM; Johansen OE; Sambevski S; Kaspers S; Pfarr E; George JT; Zinman B
Circulation; 2019 Mar; 139(11):1384-1395. PubMed ID: 30586757
[TBL] [Abstract][Full Text] [Related]
56. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
Mordi NA; Mordi IR; Singh JS; Baig F; Choy AM; McCrimmon RJ; Struthers AD; Lang CC
BMJ Open; 2017 Oct; 7(10):e018097. PubMed ID: 29042392
[TBL] [Abstract][Full Text] [Related]
57. Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY Trial.
Hoshika Y; Kubota Y; Mozawa K; Tara S; Tokita Y; Yodogawa K; Iwasaki YK; Yamamoto T; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Maruyama M; Tanabe J; Shimizu W
J Card Fail; 2022 Jan; 28(1):56-64. PubMed ID: 34425223
[TBL] [Abstract][Full Text] [Related]
58. The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial.
Sargeant JA; King JA; Yates T; Redman EL; Bodicoat DH; Chatterjee S; Edwardson CL; Gray LJ; Poulin B; Waheed G; Waller HL; Webb DR; Willis SA; Wilding JPH; Khunti K; Stensel DJ; Davies MJ
Diabetes Obes Metab; 2022 Aug; 24(8):1509-1521. PubMed ID: 35441435
[TBL] [Abstract][Full Text] [Related]
59. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
Packer M; Anker SD; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Sattar N; Brueckmann M; Jamal W; Cotton D; Iwata T; Zannad F;
J Am Coll Cardiol; 2021 Mar; 77(11):1381-1392. PubMed ID: 33736819
[TBL] [Abstract][Full Text] [Related]
60. The effect of empagliflozin on contractile reserve in heart failure: Prespecified sub-study of a randomized, double-blind, and placebo-controlled trial.
Jensen J; Omar M; Ali M; Frederiksen PH; Kistorp C; Tuxen C; Andersen CF; Larsen JH; Ersbøll MK; Køber L; Gustafsson F; Faber J; Forman JL; Møller JE; Schou M
Am Heart J; 2022 Aug; 250():57-65. PubMed ID: 35513022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
